Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.51 |
| ▸ | POLB | P06746 | 4/20 | 0.51 |
| ▸ | NSD2 | O96028 | 4/20 | 0.51 |
| ▸ | APAF1 | O14727 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | GALK1 | P51570 | 2/20 | 0.51 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.51 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.50 |
| ▸ | GAA | P10253 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615687 | 0.84 | MAPT (0.49) | MAPTPOLBNSD2APAF1KMT2A | |
| SCHEMBL28736614 | 0.84 | MAPT (0.49) | MAPTPOLBNSD2APAF1KMT2A | |
| SCHEMBL28628277 | 0.84 | MAPT (0.72) | MAPTPOLBNSD2APAF1KMT2A | |
| SCHEMBL20046757 | 0.84 | MAPT (0.67) | MAPTPOLBNSD2APAF1KMT2A | |
| SCHEMBL28443173 | 0.80 | MAPT (0.58) | MAPTPOLBNSD2APAF1KMT2A | |
| SCHEMBL28443171 | 0.79 | MAPT (0.48) | MAPTPOLBNSD2APAF1KMT2A | |
| SCHEMBL20046781 | 0.75 | NSD2 (0.64) | MAPTPOLBNSD2APAF1KMT2A | |
| SCHEMBL29881618 | 0.75 | NSD2 (0.64) | MAPTPOLBNSD2APAF1KMT2A | |
| SCHEMBL6660403 | 0.73 | MAPT (0.69) | MAPTPOLBNSD2APAF1KMT2A | |
| SCHEMBL20046958 | 0.73 | MAPT (0.60) | MAPTNSD2APAF1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459313-B2 | Aziridinyl and amino dimeric naphthoquinone compounds and use for acute myeloid leukemia | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-10 | — | — | US | disclosed |
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-10 | — | — | US | disclosed |
| WO-2018067842-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | MCL1, NPM1, ABL1 | MAPT 4723/4885POLB 2716/4885NSD2 327/4885 |
| US-11459313-B2 | Aziridinyl and amino dimeric naphthoquinone compounds and use for acute myeloid leukemia | MCL1, NPM1, ABL1 | MAPT 4723/4885POLB 2716/4885NSD2 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.